Skip to content
Search our Site
Search our site
Search our site
My PD Journey
Measurement and diagnosis
About the EPDA
Political affairs and policy
All research papers
Measurement and diagnosis
Search research papers
Resources and publications
Measurement and diagnosis research papers
Antioxidant and inflammatory biomarkers for the identification of prodromal Parkinson's disease
Conclusions: Reduced systemic antioxidant capacity is found in prodromal and overt PD and may represent, in association with olfactory loss and cardiovascular dysautonomia, a useful biomarker for an integrative, early diagnosis of PD.
15 November 2016
Frenchay dysarthria assessment (FDA-2) in Parkinson's: cross-cultural adaptation & psychometric properties of European ....
The EP-FDA-2 has shown the salient features of a valid tool that can be used by speech and language therapists in the assessment of dysarthria in PD in clinical practice as in the research field.
17 October 2016
Reduced MIBG accumulation of the parotid and submandibular glands in idiopathic Parkinson's disease
Conclusion: MIBG uptake in the parotid and submandibular glands might be a candidate biomarker for PD. The missing correlation between MIBG uptake and clinical PD parameters suggests that ASP of the extracranial sympathetic superior cervical ganglion, which innervates the major salivary glands, develops independently from the cerebral dopaminergic nigrostriatal ASP.
15 October 2016
Impaired contrast sensitivity is associated with more severe cognitive impairment in Parkinson disease
Conclusions: Impaired contrast sensitivity in PD is robustly associated with cognitive deficits, particularly executive function deficits. These results suggest that contrast sensitivity may be a useful biomarker for cognitive changes in PD and may have implications for driving safety evaluations in PD.
07 October 2016
Computer keyboard interaction as an indicator of early Parkinson's disease
This new approach discriminated early PD groups from controls with an AUC = 0.81 (n = 42/43; mean age = 59.0/60.1; women = 43%/60%;PD/controls). The performance was comparable or better than two other quantitative motor performance tests used clinically: alternating finger tapping (AUC = 0.75) and single key tapping (AUC = 0.61).
05 October 2016
Optic nerve integrity as a visuospatial cognitive predictor in Parkinson's disease
This study demonstrated that microstructural integrity in the optic nerve was distorted in PD patients, and that this nerve integrity might act as a cognitive predictor of visuospatial dysfunction.
01 October 2016
Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes
In PD participants, changes in visuospatial-executive performance and memory had the most significant impact on subjective cognitive impairment. A 1-point increase in visuospatial-executive function decreased the chance of reporting a MDS-UPDRS Q1 score of slight versus normal by a factor of 0.686 (p < 0.001) and each 1 point improvement in delayed recall decreased the odds of reporting slight cognitive impairment by a factor of 0.836 (p < 0.001).
26 September 2016
Equating scores of the University of Pennsylvania Smell Identification Test & Sniffin' Sticks test in patients with Parkinson's
Conclusion: Authors have demonstrated that one can convert UPSIT to B-SIT or Sniffin' 16, and Sniffin' 12 to 16 scores in a valid way. This can facilitate direct comparison between tests aiding future collaborative analyses and evidence synthesis.
23 September 2016
External validation of a 3-step falls prediction model in mild Parkinson's disease
Authors aimed to externally validate this model as well as to explore the value of additional predictors in 138 individuals with relatively mild PD. They found the discriminative ability of the 3-step model in identifying fallers to be comparable to previously studies and to be better than that of single predictors.
19 September 2016
Body fat distribution in Parkinson's disease: An MRI-based body fat quantification study
Results: The volume of total body fat as well as of visceral fat showed no difference between PD patients and healthy controls at baseline or at follow up. However, PD patients displayed decreased subcutaneous fat tissue (p = 0.01) and a higher visceral to subcutaneous fat ratio as compared to controls (p = 0.004).
16 September 2016
Back to Top
Add page to PDF basket
Copyright © 2016 EPDA. All Rights Reserved.
Privacy and cookies